Hypomethylating agents in MDS and AML

preview_player
Показать описание
David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, gives an overview of the use of hypomethylating agents (HMA) in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: David Sallman
  3. Institution: H. Lee Moffitt Cancer Center & Research Institute
  4. Event: VJVirtual
  5. Event: ASCO 2020
  6. Format: Interview
Рекомендации по теме
Hypomethylating agents in 0:03:14

Hypomethylating agents in MDS and AML

What are hypomethylating 0:02:02

What are hypomethylating agents and when are they used for MDS?

Mode of action 0:03:21

Mode of action of hypomethylating agents for MDS

Hypomethylating Agents in 0:03:46

Hypomethylating Agents in the Treatment of High-Risk MDS

Hypomethylating Agents in 0:06:57

Hypomethylating Agents in MDS: Factors to Consider

Hypomethylating agents for 0:01:12

Hypomethylating agents for low risk MDS

Hypomethylating Agents in 0:04:48

Hypomethylating Agents in MDS Management

Are hypomethylating agents 0:01:56

Are hypomethylating agents useful in preventing relapse in AML and MDS?

Hypomethylating Agents in 0:03:58

Hypomethylating Agents in Low-Risk MDS

Defining and Predicting 0:05:53

Defining and Predicting Response to Hypomethylating Agents in Myelodysplastic Syndrome

Hypomethylating agent based 0:01:50

Hypomethylating agent based combinations in MDS

Anti-TIM-3 antibody sabatolimab 0:06:51

Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML

Debate: Hypomethylating agents 0:20:13

Debate: Hypomethylating agents are appropriate in lower-risk MDS - Only Use With Caution

MBG453 with hypomethylating 0:07:28

MBG453 with hypomethylating agents in AML and high-risk MDS

Advantages of chemotherapy 0:03:14

Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome

Myelodysplastic Syndrome (MDS) 0:15:18

Myelodysplastic Syndrome (MDS)

Treatment of Myelodysplastic 0:06:47

Treatment of Myelodysplastic Syndromes Refractory to Hypomethylating Agent

Dr. Ai on 0:01:13

Dr. Ai on the Use of Hypomethylating Agents in Patients With MDS

Using computational algorithms 0:05:47

Using computational algorithms to predict the response of MDS patients to hypomethylating agents

Dr. Nazha on 0:02:27

Dr. Nazha on a Mutational Model to Predict Response to Hypomethylating Agents in MDS

Clinical Trial Results 0:04:50

Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Treating MDS after 1:00:13

Treating MDS after Hypomethylating Agent Failure

FDA-Approved Oral Hypomethylating 0:01:12

FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape

Investigating Hypomethylating Agents 0:08:32

Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan